Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Inflammation plays an important role in the outcome of patients with cystic fibrosis (CF). It may develop due to cystic fibrosis transmembrane conductance regulator protein dysfunction, pancreatic insufficiency, or prolonged pulmonary infection. Fecal calprotectin (FC) has been used as a noninvasive method to detect inflammation. Therefore, the aim of the current meta-analysis was to investigate the relationship between FC and phenotype severity in patients with CF. In this study, searches were conducted in PubMed, Science Direct, Scopus, and Embase databases up to August 2021 using terms such as “cystic fibrosis,” “intestine,” “calprotectin,” and “inflammation.” Only articles published in English and human studies were selected. The primary outcome was the level of FC in patients with CF. The secondary outcome was the relationship between FC and clinical severity. Statistical analysis was performed using Comprehensive Meta-Analysis software. Of the initial 303 references, only six articles met the inclusion criteria. The mean (95% confidence interval [CI]) level of FC was 256.5 mg/dL (114.1-398.9). FC levels were significantly associated with pancreatic insufficiency (mean, 243.02; 95% CI, 74.3 to 411.6; p=0.005; I2=0), pulmonary function (r=–0.39; 95% CI, –0.58 to –0.15; p=0.002; I2=60%), body mass index (r=–0.514; 95% CI, 0.26 to 0.69; p<0.001; I2=0%), and Pseudomonas colonization (mean, 174.77; 95% CI, 12.5 to 337.02; p=0.035; I2=71%). While FC is a reliable noninvasive marker for detecting gastrointestinal inflammation, it is also correlated with the severity of the disease in patients with CF.
Abstract
Inflammation plays an important role in the outcome of patients with cystic fibrosis (CF). It may develop due to cystic fibrosis transmembrane conductance regulator protein dysfunction, pancreatic insufficiency, or prolonged pulmonary infection. Fecal calprotectin (FC) has been used as a noninvasive method to detect inflammation. Therefore, the aim of the current meta-analysis was to investigate the relationship between FC and phenotype severity in patients with CF. In this study, searches were conducted in PubMed, Science Direct, Scopus, and Embase databases up to August 2021 using terms such as “cystic fibrosis,” “intestine,” “calprotectin,” and “inflammation.” Only articles published in English and human studies were selected. The primary outcome was the level of FC in patients with CF. The secondary outcome was the relationship between FC and clinical severity. Statistical analysis was performed using Comprehensive Meta-Analysis software. Of the initial 303 references, only six articles met the inclusion criteria. The mean (95% confidence interval [CI]) level of FC was 256.5 mg/dL (114.1-398.9). FC levels were significantly associated with pancreatic insufficiency (mean, 243.02; 95% CI, 74.3 to 411.6; p=0.005; I2=0), pulmonary function (r=–0.39; 95% CI, –0.58 to –0.15; p=0.002; I2=60%), body mass index (r=–0.514; 95% CI, 0.26 to 0.69; p<0.001; I2=0%), and Pseudomonas colonization (mean, 174.77; 95% CI, 12.5 to 337.02; p=0.035; I2=71%). While FC is a reliable noninvasive marker for detecting gastrointestinal inflammation, it is also correlated with the severity of the disease in patients with CF.
참고문헌 (35)
- Lubamba B, "Cystic fibrosis : insight into CFTR pathophysiology and pharmacotherapy", Clin Biochem, 45, pp.1132~1144 (2012)
- Roesch EA, "Inflammation in cystic fibrosis : an update", Pediatr Pulmonol, 53(S3), pp.S30~50 (2018)
- Cantin AM, "Inflammation in cystic fibrosis lung disease : pathogenesis and therapy", J Cyst Fibros, 14, pp.419~430 (2015)
- Belcher CN, "Protein processing and inflammatory signaling in cystic fibrosis : challenges and therapeutic strategies", Curr Mol Med, 10, pp.82~94 (2010)
- Briars G, "Intestinal inflammation in cystic fibrosis", Arch Dis Child, 84, pp.374~375 (2001)
- Mack DR, "Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction", J Pediatr, 120, pp.696~701 (1992)
- Taylor-Cousar JL, "Potential of anti-inflammatory treatment for cystic fibrosis lung disease", J Inflamm Res, 3, pp.61~74 (2010)
- Rumman N, "Calprotectin in cystic fibrosis", BMC Pediatr, 14, pp.133~ (2014)
- Bjerke K, "Distribution of macrophages and granulocytes expressing L1 protein(calprotectin)in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes", Gut, 34, pp.1357~1363 (1993)
- Parisi GF, "Severe disease in Cystic Fibrosis and fecal calprotectin levels", Immunobiology, 222, pp.582~586 (2017)
- Schnapp Z, "Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation", J Pediatr Gastroenterol Nutr, 68, pp.282~284 (2019)
- Ellemunter H, "Fecal calprotectin in cystic fibrosis and its relation to disease parameters : a longitudinal analysis for 12 years", J Pediatr Gastroenterol Nutr, 65, pp.438~442 (2017)
- Fraser-Pitt D, "Cystic fibrosis-a multiorgan protein misfolding disease", Future Sci OA, 1, pp.FSO57~ (2015)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", Int J Surg, 8, pp.336~341 (2010)
- Stang A, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses", Eur J Epidemiol, 25, pp.603~605 (2010)
- Sterne JA, "ROBINS-I : a tool for assessing risk of bias in non-randomised studies of interventions", BMJ, 355, pp.i4919~ (2016)
- Melsen WG, "The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses", Clin Microbiol Infect, 20, pp.123~129 (2014)
- Adriaanse MP, "Evidence for a cystic fibrosis enteropathy", PLoS One, 10, pp.e0138062~ (2015)
- Dhaliwal J, "Intestinal inflammation and impact on growth in children with cystic fibrosis", J Pediatr Gastroenterol Nutr, 60, pp.521~526 (2015)
- Werlin SL, "Evidence of intestinal inflammation in patients with cystic fibrosis", J Pediatr Gastroenterol Nutr, 51, pp.304~308 (2010)
- Stallings VA, "Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement : a randomized controlled trial", PLoS One, 15, pp.e0232685~ (2020)
- de Freitas MB, "Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis", PLoS One, 13, pp.e0198457~ (2018)
- Garg M, "Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children", J Cyst Fibros, 16, pp.631~636 (2017)
- Garg M, "Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old", J Cyst Fibros, 17, pp.109~113 (2018)
- Więcek S, "The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis", Prz Gastroenterol, 12, pp.38~43 (2017)
- Dorsey J, "Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine", J Cyst Fibros, 16(2), pp.S14~23 (2017)
- Marsland BJ, "Host-microorganism interactions in lung diseases", Nat Rev Immunol, 14, pp.827~835 (2014)
- Hoen AG, "Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis", J Pediatr, 167, pp.138~147 (2015)[DOI]
- Anderson JL, "Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis : a systematic review", J Cyst Fibros, 16, pp.186~197 (2017)
- Héry-Arnaud G, "The lung and gut microbiome : what has to be taken into consideration for cystic fibrosis?", J Cyst Fibros, 18, pp.13~21 (2019)
- Sabharwal S, "Gastrointestinal manifestations of cystic fibrosis", Gastroenterol Hepatol(N Y), 12, pp.43~47 (2016)
- Norkina O, "Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine", Infect Immun, 72, pp.6040~6049 (2004)
- Werlin S, "Enteropathy – a new finding in cystic fibrosis", J Cyst Fibros, 7(2), pp.S79~ (2008)
- Bruzzese E, "Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG : a randomised clinical trial", PLoS One, 9, pp.e87796~ (2014)
- Coffey MJ, "Gut microbiota in children with cystic fibrosis : a taxonomic and functional dysbiosis", Sci Rep, 9, pp.18593~ (2019)